Comparable stake leader
Fu-Feng Kuo
SEC ownership of Jyong Biotech Ltd.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001954488.
Disclosed value leader
Fu-Feng Kuo
Comparable rows
0/11
Latest evidence
30 Jun 2026
- Public ticker
- MENS on Nasdaq
- Parsed ownership sources
-
3/4/5 and 13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Fu-Feng Kuo
Ranking: Comparable ownership first, then disclosed value
- Latest parsed ownership date
-
30 Jun 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001954488
- Issuer location
- New Taipei City
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
1 signal
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Jyong Biotech Ltd. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Fu-Feng Kuo
Disclosed value leader
Fu-Feng Kuo
Comparable rows
0/11
Latest evidence
30 Jun 2026
3/4/5
13F
Highest disclosed value: $54,501,425
11 rows are not safely comparable across share classes.
Showing 1-8 of 11 holder rows.
Quick read
Fu-Feng Kuo has the largest disclosed position value at $54.5M.
0 of 11 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Fu-Feng Kuo's linked filing trail.
Disclosed position value
Top 5
Fu-Feng Kuo
$54.5M
BlackRock, Inc.
$538.9K
China Universal Asset Management ...
$25K
State of Wyoming
$23.2K
Hsu Feng-Lin
$11.8K
Value bars compare disclosed positions; verify each figure against the linked filing evidence.
Detailed SEC evidence table Showing 1-8 of 11 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Fu-Feng Kuo |
3/4/5
CEO, Director, 10%+ Owner
|
—
class O/S missing
|
$54,501,425
25,349,500 shares
|
— | 08 Apr 2026 |
| BlackRock, Inc. |
13F
Company
|
—
class O/S missing
|
$538,856
260,317 shares
|
— | 30 Jun 2026 |
| China Universal Asset Management Co., Ltd. |
13F
Company
|
—
class O/S missing
|
$25,047
12,100 shares
|
— | 30 Jun 2026 |
| State of Wyoming |
13F
Company
|
—
class O/S missing
|
$23,201
11,208 shares
|
— | 30 Jun 2026 |
| Hsu Feng-Lin |
3/4/5
Director
|
—
class O/S missing
|
$11,850
3,000 shares
|
— | 01 Apr 2026 |
| Hsu Ming Tsan |
3/4/5
Director
|
—
class O/S missing
|
$11,850
3,000 shares
|
— | 01 Apr 2026 |
| Mirae Asset Global Investments Co., Ltd. |
13F
Company
|
—
class O/S missing
|
$7,038
3,400 shares
|
— | 30 Jun 2026 |
| CITIGROUP INC |
13F
Company
|
—
class O/S missing
|
$5,177
2,501 shares
|
— | 30 Jun 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 15 Aug 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-6 of 6 reporting-owner rows connected to Jyong Biotech Ltd.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
6
Largest Forms 3/4/5 holder
Fu-Feng Kuo
Net 12M change
$0
Latest report
13 Apr 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Fu-Feng Kuo | CEO, Director, 10%+ Owner | $54,501,425 | Mixed | 08 Apr 2026 | ||
| Hsu Feng-Lin | Director | $11,850 | Mixed | 01 Apr 2026 | ||
| Hsu Ming Tsan | Director | $11,850 | Mixed | 01 Apr 2026 | ||
| Chi Pang-Chieh | Director | Mixed | 01 Apr 2026 | |||
| Fan Hung-Shu | Director | Mixed | 01 Apr 2026 | |||
| Wei (vivi) Zhang | Cfo | Mixed | 13 Apr 2026 |
Recent insider transactions for Jyong Biotech Ltd.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Fu-Feng Kuo | MENS | Common Stock | 0 | 25,349,500 | 08 Apr 2026 | Held through Perfect Minds Co., Ltd, a Seychelles company. | ||||
| Hsu Ming Tsan | MENS | Common Stock | 0 | 3,000 | 01 Apr 2026 | Direct | ||||
| Hsu Feng-Lin | MENS | Common Stock | 0 | 3,000 | 01 Apr 2026 | Direct | ||||
| Hsu Feng-Lin | MENS | Common Stock | 0 | 3,000 | 01 Apr 2026 | Direct |
* marks a reported price that did not pass the local price check.